A BILL 
To support the advanced manufacturing technologies pro-
gram of the Food and Drug Administration, to establish 
National Centers of Excellence in Advanced Pharma-
ceutical Manufacturing, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Securing America’s 
4
Medicine Cabinet Act of 2021’’. 
5
19:39 Jan 12, 2021
H70
2 
•HR 70 IH
SEC. 2. ADVANCED MANUFACTURING TECHNOLOGIES PRO-
1
GRAM. 
2
Subchapter A of chapter V of the Federal Food, 
3
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
4
ed by adding at the end the following: 
5
‘‘SEC. 524B. ADVANCED MANUFACTURING TECHNOLOGIES 
6
PROGRAM. 
7
‘‘(a) IN GENERAL.—Not later than 1 year after the 
8
date of enactment of the Securing America’s Medicine 
9
Cabinet Act of 2021, the Secretary shall continue in effect 
10
the program to evaluate and approve new drug manufac-
11
turing technologies that are included in an application, or 
12
supplement to an application, for a drug under subsection 
13
(b) or (j) of section 505 of this Act or for a biological 
14
product submitted under subsection (a) or (k) of section 
15
351 of the Public Health Service Act. 
16
‘‘(b) DESIGNATION.—The Secretary shall designate a 
17
method of manufacturing a drug as an advanced manufac-
18
turing technology under this section if the drug manufac-
19
turer demonstrates that such technology is likely to— 
20
‘‘(1) prevent or resolve a drug shortage; 
21
‘‘(2) maintain an adequate supply of critical 
22
medications for national emergencies; or 
23
‘‘(3) promote the adoption of innovative ap-
24
proaches to drug product design and manufacturing. 
25
19:39 Jan 12, 2021
H70
3 
•HR 70 IH
‘‘(c) CONSULTATION.—If the Secretary designates a 
1
method of manufacturing as an advanced manufacturing 
2
technology under this section, the Secretary shall take ac-
3
tions to expedite the development and implementation of 
4
such method of manufacture for purposes of approval of 
5
the application under subsection (c) or (j) of section 505 
6
of this Act or subsection (a) or (k) of section 351 of the 
7
Public Health Service Act, which may include, as appro-
8
priate— 
9
‘‘(1) holding meetings between the sponsor of 
10
the application and appropriate Food and Drug Ad-
11
ministration staff throughout the development of the 
12
technology; 
13
‘‘(2) providing timely advice to, and interactive 
14
communication with, the sponsor regarding the de-
15
velopment of the technology; and 
16
‘‘(3) involving senior managers and experienced 
17
staff of the Food and Drug Administration, as ap-
18
propriate, in a collaborative, cross-disciplinary review 
19
of the method of manufacturing. 
20
‘‘(d) EVALUATION
OF
AN ADVANCED MANUFAC-
21
TURING TECHNOLOGY.— 
22
‘‘(1) PACKAGE.—A sponsor who receives des-
23
ignation of an advanced manufacturing technology 
24
under this section shall provide the Secretary with a 
25
19:39 Jan 12, 2021
H70
4 
•HR 70 IH
package of scientific evidence supporting the imple-
1
mentation of the advanced manufacturing technology 
2
in a particular context-of-use. 
3
‘‘(2) EVALUATION.—Within 90 days of receiv-
4
ing the package, the Secretary shall determine 
5
whether a designated advanced manufacturing tech-
6
nology is validated for the proposed context of use 
7
based on the scientific merit the supporting evidence 
8
provided by the sponsor. 
9
‘‘(3) EFFECT OF APPROVAL.—Upon approval, 
10
the same sponsor may rely upon the advanced man-
11
ufacturing technology for use across multiple manu-
12
facturing product lines within the same context-of- 
13
use without having to re-submit data to the Sec-
14
retary validating the underlying technology. 
15
‘‘(e) IMPLEMENTATION AND REPORTING.— 
16
‘‘(1) PUBLIC
MEETING.—The Secretary shall 
17
publish in the Federal Register a notice of a public 
18
meeting to be held no later than 1 year after the 
19
date of enactment of the Securing America’s Medi-
20
cine Cabinet Act of 2021 to discuss and obtain input 
21
and recommendations from stakeholders regarding 
22
the goals and scope of, and a suitable framework 
23
and procedures and requirements for, the program 
24
under this section. 
25
19:39 Jan 12, 2021
H70
5 
•HR 70 IH
‘‘(2) 
PROGRAM
GUIDANCE.—The 
Secretary 
1
shall— 
2
‘‘(A) not later than 1 year after the date 
3
of enactment of the Securing America’s Medi-
4
cine Cabinet Act of 2021, issue draft guidance 
5
regarding the goals and implementation of the 
6
program under this section; and 
7
‘‘(B) not later than 2 years after the date 
8
of enactment of the Securing America’s Medi-
9
cine Cabinet Act of 2021, issue final guidance 
10
with respect to the implementation of such pro-
11
gram. 
12
‘‘(3) REPORT.—The Secretary shall make avail-
13
able on the internet website of the Food and Drug 
14
Administration an annual report on the progress of 
15
the program under this section.’’. 
16
SEC. 3. NATIONAL CENTER OF EXCELLENCE IN ADVANCED 
17
PHARMACEUTICAL MANUFACTURING. 
18
Chapter X of the Federal Food, Drug, and Cosmetic 
19
Act (21 U.S.C. 391 et seq.) is amended by adding at the 
20
end the following: 
21
19:39 Jan 12, 2021
H70
6 
•HR 70 IH
‘‘SEC. 1015. NATIONAL CENTER OF EXCELLENCE IN AD-
1
VANCED 
PHARMACEUTICAL 
MANUFAC-
2
TURING. 
3
‘‘(a) IN GENERAL.—The Secretary shall designate in-
4
stitutions of higher education as National Centers of Ex-
5
cellence in Advanced Pharmaceutical Manufacturing, in-
6
cluding continuous pharmaceutical manufacturing. 
7
‘‘(b) ELIGIBILITY.—To be eligible for designation 
8
under subsection (a) an entity shall— 
9
‘‘(1) be an institution of higher education; 
10
‘‘(2) demonstrate— 
11
‘‘(A) the physical and technical capacity 
12
for research and development of advanced phar-
13
maceutical manufacturing; 
14
‘‘(B) a record of transferring scientific 
15
knowledge to the marketplace; 
16
‘‘(C) scalable manufacturing knowledge, 
17
which may be through collaborations of other 
18
institutions of higher education, biopharma-
19
ceutical manufacturers, or other entities; 
20
‘‘(D) the ability to train a future workforce 
21
for research on and implementation of advanced 
22
pharmaceutical manufacturing; and 
23
‘‘(E) the ability to support Federal agen-
24
cies with technical assistance for advanced 
25
pharmaceutical technologies, with an emphasis 
26
19:39 Jan 12, 2021
H70
7 
•HR 70 IH
on creating a secure national pharmaceutical 
1
stockpile and the ability to rapidly address drug 
2
shortages; and 
3
‘‘(3) submit an application to the Secretary at 
4
such time, in such form, and in such manner as the 
5
Secretary may require. 
6
‘‘(c) TERMINATION.—The Secretary may terminate 
7
the designation of an entity designated under subsection 
8
(a) upon a determination that the entity no longer meets 
9
the requirements of subsection (b). 
10
‘‘(d) ANNUAL REPORT.—Not later than 1 year after 
11
the date on which the first designation is made under sub-
12
section (a), and annually thereafter, the Secretary shall 
13
submit a report to Congress on the activities of the entities 
14
designated under such subsection. 
15
‘‘(e) AUTHORIZATION
OF
APPROPRIATIONS.—To 
16
carry out this section, there are authorized to be appro-
17
priated $100,000,000 for the period of fiscal years 2022 
18
through 2025.’’. 
19
Æ 
19:39 Jan 12, 2021
H70
